What Is Perimenopause? Stages, Symptoms, and How Long It Lasts

The short answer

The most useful thing to understand about this window is that it is not a slow slide downward. Estradiol in perimenopause is erratic rather than uniformly low, and some of the worst symptoms happen during spikes, not deficits. That is why a single blood test taken on an arbitrary Tuesday can look completely normal in a woman with drenching night sweats, flooding periods, and four months of insomnia. The Stages of Reproductive Aging Workshop +10 (STRAW+10), the international staging system published in 2012, made the bleeding calendar the primary criterion for exactly this reason: cycle behavior is more reliable than a random FSH or estradiol draw.

This page covers how STRAW+10 divides the transition into early and late stages, what actually changes between them, the full symptom range beyond hot flashes, how long symptoms last based on the SWAN cohort, which bleeding patterns need evaluation, how perimenopause is distinguished from primary ovarian insufficiency and thyroid disease, when contraception is still required, and what treatment options exist.

What perimenopause actually is, physiologically

Across the reproductive years the ovary contains a declining pool of follicles. Each cycle, a cohort of follicles is recruited, one becomes dominant, ovulation occurs, and the corpus luteum produces progesterone for the second half of the cycle. Perimenopause begins when that pool becomes small enough that recruitment gets unreliable. The pituitary compensates by raising FSH to push the remaining follicles harder. Sometimes this overshoots, producing a cycle with unusually high estradiol. Sometimes no dominant follicle emerges at all, ovulation is skipped, no corpus luteum forms, and no meaningful progesterone is made for that cycle.

This produces the two mechanical realities of the transition. First, estradiol is volatile rather than low, at least early on, which explains breast tenderness, heavier bleeding, and migraine patterns that some women find get worse before they get better. Second, progesterone exposure falls earlier and more consistently than estrogen exposure, because progesterone depends on ovulation actually happening. Cycles that look normal on a calendar can already be anovulatory.

Unopposed estrogen, meaning estrogen acting on the uterine lining without the counterbalancing effect of progesterone from a corpus luteum, is why the endometrium can build up and then shed heavily or unpredictably in perimenopause. It is also the reason clinicians take new heavy or intermenstrual bleeding in this age group seriously rather than dismissing it as an expected part of the change.

Only in the late transition does estradiol production fall in a sustained way. That is when the symptom picture typically shifts from volatility-driven complaints toward deficiency-driven ones such as vaginal dryness, urinary urgency, and more consistent vasomotor symptoms.

How STRAW+10 stages the transition

STRAW+10, published in 2012, is the reference staging system used in research and increasingly in clinical practice. It anchors everything to the final menstrual period (FMP), which can only be identified retrospectively after twelve months have passed. Stages before the FMP carry negative numbers, stages after it carry positive numbers. The perimenopause, or menopausal transition, comprises stages -2 and -1, and by convention perimenopause is often extended to include the first twelve months after the FMP.

The critical design choice in STRAW+10 is that the principal criterion for each stage is menstrual, not endocrine. Hormone measurements are listed as supportive criteria, useful in research or in specific clinical situations, but they are not what defines the stage. A woman is in the early menopausal transition because her cycles have started varying, not because her FSH crossed a threshold.

STRAW+10 also notes that its criteria apply less cleanly to certain groups, including women who have had a hysterectomy or endometrial ablation, women using hormonal contraception that suppresses bleeding, and women with conditions such as polycystic ovary syndrome where cycles were already irregular. For these women, staging leans more on symptoms and, where relevant, on hormone testing that the system otherwise treats as secondary.

Early versus late transition: what actually changes

The early menopausal transition, STRAW+10 stage -2, is defined by variability. Consecutive cycles differ by seven days or more, and this happens repeatedly rather than once. Practically, a woman who has had 28-day cycles for two decades notices a 24-day cycle, then a 33-day one, then a 26-day one. Periods are still happening every month or nearly so. Many women in this stage are told their labs are normal and that they are too young for menopause, which is a misreading of the criteria, since the criteria never required abnormal labs in the first place.

The late menopausal transition, stage -1, begins with the first interval of 60 days or more without bleeding. This is the point at which follicular activity has become sporadic enough that whole cycles are being missed. STRAW+10 notes that FSH drawn at a random time in this stage tends to run higher, above roughly 25 IU/L, but treats this as supportive rather than defining, precisely because a single value can still land anywhere. The late transition is typically the shortest of the stages and the one during which vasomotor symptoms most often become frequent and predictable.

The symptom profile tends to shift with the stage. Early transition complaints skew toward volatility: heavier or longer periods, worse premenstrual mood, breast tenderness, migraines clustered around bleeding, and sleep that breaks in the second half of the cycle. Late transition complaints skew toward withdrawal: night sweats, more global insomnia, vaginal dryness, and reduced libido. Neither pattern is universal, and plenty of women experience both simultaneously.

Knowing which stage you are in changes practical decisions. In the early transition, contraception is still clearly needed, cyclic bleeding problems can often be addressed with methods that also provide contraception, and treatment is aimed at stabilizing swings. In the late transition, the conversation more often turns to hormone therapy for symptom control and to the question of when contraception can be stopped.

The full symptom range, not just hot flashes

Vasomotor symptoms, meaning hot flashes and night sweats, are the most recognized feature and the one with the strongest evidence base for treatment, but they are far from the only manifestation. Estrogen receptors are present in the brain, blood vessels, bone, skin, urogenital tissue, and joints, so a fluctuating and eventually declining estrogen supply produces effects in all of those places.

Sleep disruption is one of the most common and most underestimated complaints. It is not always caused by night sweats. Many women describe waking at 3 a.m. fully alert, without any heat sensation. Because so much of the daytime symptom load in perimenopause, including irritability, low mood, poor concentration, and fatigue, is amplified by fragmented sleep, sleep is often the highest-yield thing to address first.

Cognitive complaints, usually described as brain fog, word-finding trouble, or losing the thread mid-sentence, are commonly reported during the transition and are frequently the symptom that alarms women most. Mood changes also cluster in this window, with some women experiencing a first depressive episode and others a recurrence of one they had years earlier, sometimes postpartum.

Genitourinary symptoms deserve separate mention because they behave differently from the rest. The North American Menopause Society's 2020 position statement on genitourinary syndrome of menopause describes it as a chronic and progressive condition: vaginal dryness, burning, painful sex, urinary urgency, and recurrent urinary tract infections do not typically improve on their own with time, unlike hot flashes, which usually eventually recede. That distinction matters, because waiting it out is a reasonable strategy for one and not for the other.

How long perimenopause and its symptoms last

The transition itself and the symptoms it causes are two different clocks, and conflating them is the source of most bad expectation-setting. The transition, measured from the first persistent cycle irregularity to twelve months after the final period, commonly runs several years. Vasomotor symptoms typically outlast it.

The Study of Women's Health Across the Nation (SWAN), reported in JAMA Internal Medicine in 2015, followed a multiethnic cohort of women through the transition and found that the median total duration of frequent vasomotor symptoms was 7.4 years. The median duration of symptoms persisting after the final menstrual period was 4.5 years. These are medians, meaning half of women experienced longer.

SWAN also found that timing of onset predicted duration. Women whose frequent hot flashes began while they were still premenopausal or in the early transition had the longest total duration, with a median exceeding 11.8 years. Women whose symptoms did not begin until after the final menstrual period had the shortest, with a median of roughly 3.4 years. In other words, early onset is not a sign that you are getting it over with early. It usually means the opposite.

The practical consequence is that advice to simply wait it out is often advice to wait most of a decade. That does not mean everyone needs treatment. It means the decision should be made with an accurate time horizon rather than an assumption that this resolves in a year or two.

Why FSH and estradiol testing misleads in this window

FSH rises as ovarian follicle reserve falls, which makes it a tempting test. The problem is that in perimenopause it does not rise smoothly. Within a single month a woman in the late transition can produce an FSH consistent with postmenopause and then, after a spontaneous ovulatory cycle, a value squarely in the premenopausal range. Estradiol behaves the same way and can be high, normal, or low depending on which day of an irregular cycle the blood is drawn.

This is why STRAW+10 places bleeding pattern first and relegates endocrine measures to supportive criteria. For a woman in her mid-forties with changing cycles and typical symptoms, an FSH result almost never changes what happens next. A normal value does not exclude perimenopause and an elevated one does not confirm that periods have ended. Testing in this situation mostly generates false reassurance in one direction or false certainty in the other.

There are situations where hormone testing genuinely helps. If a woman is under 40, testing is essential, because loss of ovarian function at that age is primary ovarian insufficiency and carries different implications. If a woman has had a hysterectomy but retains her ovaries, there is no bleeding pattern to read. If symptoms are atypical, if there is galactorrhea or visual change suggesting a pituitary cause, or if a different endocrine diagnosis is plausible, testing is targeted rather than reflexive.

Salivary hormone testing and multi-point hormone panels marketed directly to consumers deserve specific caution. The National Academies review of compounded bioidentical hormone therapy and the American College of Obstetricians and Gynecologists' 2023 clinical consensus both address the practice of using such testing to titrate compounded hormone preparations, and neither supports it. Hormone levels in perimenopause are moving targets, and dosing to a number rather than to symptoms has no established benefit.

Which bleeding changes are expected and which need evaluation

Irregular bleeding is the defining feature of perimenopause, so a certain amount of unpredictability is exactly what the diagnosis predicts. Cycles that shorten, lengthen, skip, or vary in flow are consistent with the transition. What is not automatically consistent with it is bleeding that is very heavy, that occurs between periods, that follows sex, or that occurs at all after menopause has been established.

ACOG's patient guidance on perimenopausal bleeding makes the distinction directly: changes in menstrual pattern are common during the transition, but certain patterns warrant evaluation because the same age group carries a rising background risk of endometrial hyperplasia and endometrial cancer, and because unopposed estrogen exposure in anovulatory cycles is itself a driver of endometrial buildup. Evaluation is not an accusation that something is wrong; it is how those possibilities get excluded.

ACOG's guidance on heavy menstrual bleeding gives concrete thresholds that are easier to act on than the vague instruction to report bleeding that seems excessive. Soaking through a pad or tampon every hour for several consecutive hours, needing to double up on protection, waking at night to change protection, bleeding for longer than seven days, and passing clots the size of a quarter or larger all describe bleeding that should be assessed.

Any bleeding after menopause has been established, meaning after twelve consecutive months without a period, is treated as requiring evaluation regardless of how light it is or how easily it might be explained. ACOG's committee opinion on transvaginal ultrasonography addresses the role of imaging in this workup, alongside endometrial sampling where indicated. Most postmenopausal bleeding turns out to have a benign cause, most commonly atrophy of the vaginal and endometrial tissue, but it is not something to watch and see.

Perimenopause versus primary ovarian insufficiency

Primary ovarian insufficiency (POI) means the ovaries stop functioning normally before age 40. MedlinePlus describes it as producing irregular or absent periods, infertility, and symptoms that overlap heavily with menopause, including hot flashes and vaginal dryness. It is not simply perimenopause arriving on an early schedule, and the distinction has real consequences.

The first difference is diagnostic. Loss of ovarian function before 40 requires investigation rather than reassurance. Recognized causes include genetic conditions such as Turner syndrome and fragile X premutation, autoimmune disease affecting the ovaries, and treatment-related causes including chemotherapy and pelvic radiation. In many cases no cause is identified, but the search itself can uncover conditions that matter independently.

The second difference is long-term risk. Losing estrogen decades earlier than expected means decades more of exposure to the consequences, and MedlinePlus notes increased risk of osteoporosis and heart disease in POI. This is why hormone therapy in POI is generally framed as replacement of what should physiologically be present until the usual age of menopause, a different calculation from symptom-driven hormone therapy started at 51.

The third difference is fertility counseling. Ovarian function in POI can be intermittent rather than absent, and MedlinePlus notes that spontaneous pregnancy remains possible in a small proportion of women with the diagnosis. That cuts both ways: women who want to conceive should not be told it is impossible, and women who do not should not be told contraception is unnecessary.

Perimenopause versus thyroid disease and other mimics

Thyroid dysfunction is the classic mimic because it is common in midlife women and because its symptom list overlaps almost point for point with the transition. Hypothyroidism can produce fatigue, low mood, cold intolerance, dry skin, hair thinning, and heavier or more frequent periods. Hyperthyroidism can produce heat intolerance, sweating, palpitations, anxiety, insomnia, and lighter or less frequent periods. Either can be mistaken for perimenopause, and either can coexist with it.

The practical resolution is that thyroid function testing is straightforward, inexpensive, and definitive in a way that FSH testing in this window is not. That is the inversion worth remembering: the hormone test most women ask for in perimenopause is the one that helps least, and the one that is often skipped is the one that can change the diagnosis outright.

Other conditions worth considering when symptoms do not fit cleanly include iron deficiency with or without anemia, which is common when perimenopausal bleeding is heavy and which independently causes fatigue, breathlessness, and poor concentration; obstructive sleep apnea, which presents as unrefreshing sleep and daytime fatigue and is easy to miss in women; depression and anxiety disorders, which may be primary rather than secondary; and medication effects.

The point is not to defer the perimenopause diagnosis indefinitely while chasing alternatives. Perimenopause is a clinical diagnosis made from pattern and age, and in a woman with typical cycle changes and typical symptoms it is usually the answer. The point is that a short, targeted workup costs little and occasionally finds something else entirely.

Contraception during perimenopause

Fertility falls sharply during the transition, but it does not reach zero when cycles become irregular. Ovulation in perimenopause is unpredictable rather than absent, which means it can occur after a two-month gap with no warning. The Office on Women's Health is explicit that pregnancy remains possible until menopause is confirmed, and menopause is only confirmed retrospectively by twelve consecutive months without a period.

This creates the practical rule: contraception is needed until that twelve-month mark has been reached. Because the transition also produces long gaps between periods, women frequently assume they have passed that mark when they have not, and the counting restarts with each bleed. How long that takes in an individual case is a question for your own clinician, since the count depends entirely on your bleeding pattern and cannot be predicted from age alone.

Hormonal contraception complicates staging, which is a trade-off worth naming rather than avoiding. Methods that suppress or eliminate bleeding remove the very signal STRAW+10 uses to determine stage, so a woman on a continuous combined pill or with a hormonal IUD in place cannot be staged by bleeding pattern. STRAW+10 acknowledges this limitation directly. It does not mean these methods should be avoided; it means the timing conversation has to happen differently.

There is also overlap in benefit. Several contraceptive methods address perimenopausal problems at the same time as preventing pregnancy, particularly heavy or unpredictable bleeding. Which method fits depends on individual medical history, including migraine with aura, blood pressure, smoking status, clotting history, and breast cancer history, all of which change the options meaningfully. This is a conversation to have specifically, not a category to choose generically.

Treatment options: hormone therapy

The North American Menopause Society's 2022 hormone therapy position statement remains the reference document for this decision in the United States. Its core position is that hormone therapy is the most effective treatment available for vasomotor symptoms and for genitourinary syndrome of menopause, and that for healthy women who are under 60 or within 10 years of menopause onset, and who do not have contraindications, the balance of benefit and risk is generally favorable when treatment is directed at bothersome symptoms.

That framing is deliberately conditional. NAMS emphasizes individualizing the decision based on personal risk factors, including cardiovascular disease, venous thromboembolism, and breast cancer history, and revisiting it periodically rather than setting it once. It also notes that risks differ by formulation, dose, route of administration, and timing of initiation, so hormone therapy is not one intervention with one risk profile.

One structural point applies to every woman with an intact uterus: estrogen taken systemically must be accompanied by adequate progestogen. Estrogen alone stimulates the endometrium, and without opposition that stimulation raises the risk of endometrial hyperplasia and cancer. Women who have had a hysterectomy generally use estrogen alone.

For women whose only bothersome symptoms are genitourinary, NAMS's 2020 position statement supports low-dose vaginal estrogen rather than systemic therapy, since the problem is local and local treatment delivers minimal systemic exposure. Other options in that statement include vaginal DHEA and the oral agent ospemifene, alongside non-hormonal moisturizers and lubricants. FDA prescribing information for the estradiol vaginal ring is one example of an approved local product with published labeling that a reader can review directly.

Compounded bioidentical hormone therapy sits outside this evidence base. ACOG's 2023 clinical consensus and the National Academies review both address custom-compounded preparations, which are not FDA-approved, are not subject to the same manufacturing consistency requirements, and lack the safety and efficacy data supporting approved products. The phrase bioidentical is often used to imply superiority, but FDA-approved products containing 17-beta estradiol and micronized progesterone are themselves bioidentical and are backed by regulated manufacturing and published labeling.

Treatment options beyond systemic hormones

Not every woman wants hormone therapy, and not every woman is a candidate for it. Non-hormonal prescription options for vasomotor symptoms exist and are addressed in the professional guidance, and the choice among them often turns on comorbidity: a woman who also has mood symptoms, sleep problems, or neuropathic pain may find one option addresses two problems at once. These require a prescribing conversation, and this page is informational rather than prescriptive.

Behavioral and environmental approaches have modest but real effects on symptom burden, particularly for sleep. Layered clothing, a cooler bedroom, avoiding known individual triggers, limiting alcohol close to bedtime, and consistent sleep timing are unglamorous but cost nothing. Cognitive behavioral therapy for insomnia is worth asking about specifically when sleep is the dominant complaint, because it targets the mechanism rather than sedating around it.

Testosterone is frequently discussed in perimenopause marketing, so the actual evidence position is worth stating precisely. The 2019 Global Consensus Position Statement on testosterone therapy for women and the accompanying systematic review and meta-analysis in Lancet Diabetes and Endocrinology concluded that the only evidence-based indication is hypoactive sexual desire disorder in postmenopausal women, and that evidence does not support its use for other symptoms such as fatigue, mood, cognition, or bone health. The consensus also notes that no female-specific formulation is approved in most countries, including the United States, and that if testosterone is used, blood levels should remain within the premenopausal physiological range rather than being pushed higher.

For sexual symptoms more broadly, the International Society for the Study of Women's Sexual Health published a clinical practice guideline in 2021 that sets out how these problems are assessed and managed. The reason this matters is that low desire, pain with sex, and reduced arousal have different causes and different treatments, and collapsing them into a single hormonal problem often produces the wrong intervention.

What a useful perimenopause appointment looks like

The single most valuable thing to bring is a bleeding record covering at least the last six to twelve months: the start date of each period, the length of each cycle, and a rough note on flow. This is what STRAW+10 stages on, and it is information no test can reconstruct. A cycle-tracking app export, a paper calendar, or a note on a phone all work equally well.

The second most valuable thing is a symptom record with frequency and impact, not just presence. Waking twice a week is a different problem from waking nightly. Hot flashes that are noticeable are a different problem from hot flashes that force a change of clothes at work. Treatment decisions in this area are driven by how bothersome symptoms are, which means the clinician needs a measure of bother, not just a list.

It also helps to arrive with the relevant history that changes the options: personal or family history of breast, ovarian, or endometrial cancer; blood clots; stroke or heart attack; migraine with aura; liver disease; unexplained bleeding; and current medications and supplements. These are the specific items that move hormone therapy from a straightforward conversation to a more careful one.

Finally, name your priority. Symptom control, contraception, bleeding management, and long-term bone or cardiovascular risk are related but distinct goals, and the best option for one is not always the best for another. A visit that starts with what matters most to you tends to end with a plan rather than a printout.

Where perimenopause ends and what changes after

Perimenopause ends twelve months after the final menstrual period. Because the final period can only be identified in hindsight, there is no moment at which anything is announced. Most women realize they have crossed the line some months after the fact, when they count backward and find a full year without bleeding. The Office on Women's Health puts the average age of that point in the United States at around 52.

Some things improve after that line and some do not. Vasomotor symptoms typically peak in the early postmenopausal years and then recede, though SWAN's finding of a median 4.5 years of persistence after the final period means that recession is measured in years rather than months. Erratic bleeding stops being an issue by definition, and with it the unpredictability that many women find hardest to plan around.

Genitourinary symptoms move the other way. NAMS's 2020 statement characterizes genitourinary syndrome of menopause as chronic and progressive without treatment, which means these symptoms tend to appear later and worsen rather than resolve. Women who assumed that everything eventually settles are frequently caught off guard by symptoms arriving several years after their last period.

Long-term health considerations also come into focus. Bone loss accelerates around the transition, and cardiovascular risk profiles shift. Neither is a reason for alarm, but both are reasons that a postmenopausal check-in should cover more than symptom relief, including blood pressure, lipids, and a conversation about whether bone density assessment is appropriate for your risk profile.

One final point about the whole span: the fact that perimenopause is universal does not mean symptoms have to be endured. Universal and untreatable are different claims, and the professional guidance from NAMS and ACOG is uniformly built around treating bothersome symptoms rather than waiting them out.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• Based on my cycle records over the past year, which STRAW+10 stage am I in — early transition, late transition, or still late reproductive?
• Given my age and symptoms, would an FSH or estradiol test actually change anything about my care, or should we check thyroid function and iron instead?
• My bleeding has changed in this specific way — does this pattern need evaluation such as an ultrasound or endometrial sampling, or is it consistent with the transition?
• Given my personal and family medical history, am I a candidate for systemic hormone therapy, and which formulation and route would you consider first?
• If I have a uterus and take estrogen, what progestogen would you use alongside it and at what schedule?
• How long do I need to keep using contraception, and how will we decide when it is safe to stop given my cycle pattern?
• My main problem is vaginal dryness and painful sex rather than hot flashes — would local vaginal treatment be more appropriate than systemic therapy for me?

Frequently asked questions

What is the first sign of perimenopause?

The first sign recognized by the STRAW+10 staging system is a change in cycle length: a persistent difference of seven days or more between consecutive cycles, recurring within a ten-cycle window. Many women notice symptoms before that, most often worse sleep, more intense premenstrual mood changes, or heavier periods. Because these appear while periods are still essentially monthly, they are frequently attributed to stress rather than to the transition.

Can a blood test confirm perimenopause?

Not reliably. FSH and estradiol fluctuate substantially during the transition, and a single measurement can fall in the premenopausal range in a woman with clear symptoms or in the postmenopausal range in a woman who then has a normal cycle. STRAW+10 makes bleeding pattern the primary criterion and treats hormone levels as supportive. Testing is genuinely important in women under 40, in women who have had a hysterectomy, and when a different diagnosis such as thyroid disease is being considered.

How long does perimenopause last?

The transition itself, from first persistent cycle irregularity to twelve months after the final period, commonly runs several years. Symptoms usually outlast it. In the SWAN cohort the median total duration of frequent vasomotor symptoms was 7.4 years, and the median duration of symptoms continuing after the final menstrual period was 4.5 years. Women whose symptoms began before their cycles changed had the longest total duration, with a median exceeding 11.8 years.

Can I get pregnant during perimenopause?

Yes. Ovulation during the transition is unpredictable rather than absent, and the Office on Women's Health states that pregnancy remains possible until menopause is confirmed. Confirmation requires twelve consecutive months without a period, counted from the most recent bleed. Because long gaps between periods are typical in the late transition, it is easy to assume you have passed that mark when a subsequent period restarts the count.

Is heavy bleeding normal in perimenopause?

Some increase in flow is common because cycles without ovulation leave the uterine lining exposed to estrogen without progesterone, allowing it to build up before shedding. But ACOG describes specific patterns that need evaluation rather than acceptance: soaking through a pad or tampon hourly for several hours, needing double protection, waking at night to change, bleeding longer than seven days, or passing blood clots the size of a quarter or larger. Bleeding between periods, after sex, or any bleeding after menopause is established also needs assessment.

What is the difference between perimenopause and primary ovarian insufficiency?

Primary ovarian insufficiency means the ovaries stop working normally before age 40, and MedlinePlus describes it as causing irregular or absent periods, infertility, and menopause-like symptoms. It is a distinct diagnosis requiring investigation of causes, which can include genetic conditions, autoimmune disease, chemotherapy, or radiation. It also carries increased long-term risk of osteoporosis and heart disease because estrogen is lost decades earlier than expected, which is why hormone therapy in POI is approached as replacement rather than as optional symptom relief.

Do hot flashes mean my estrogen is low?

Not necessarily, and not in a way a single test can show. Estradiol in perimenopause is erratic rather than steadily low, and vasomotor symptoms can occur during withdrawal from a high level as well as during a low one. This is one of the main reasons a normal estradiol result does not contradict a symptom picture that clearly points to the transition.

Is hormone therapy safe during perimenopause?

The North American Menopause Society's 2022 position statement holds that for healthy women under 60 or within ten years of menopause onset who have bothersome symptoms and no contraindications, the balance of benefit and risk is generally favorable. Risk differs by formulation, dose, route, and timing, and personal history including breast cancer, blood clots, stroke, and cardiovascular disease changes the calculation. Anyone with a uterus taking systemic estrogen needs adequate progestogen to protect the endometrium. This is a decision to make individually with a clinician, not from a general rule.

Are compounded bioidentical hormones better?

There is no evidence that they are. ACOG's 2023 clinical consensus and the National Academies review both address custom-compounded preparations and note that they are not FDA-approved, are not held to the same manufacturing consistency standards, and lack the safety and efficacy data supporting approved products. FDA-approved 17-beta estradiol and micronized progesterone are themselves bioidentical, so the marketing term does not describe a difference in molecule, only in regulatory status.

Should I take testosterone for perimenopause symptoms?

The 2019 Global Consensus Position Statement and the accompanying systematic review concluded that the only evidence-based indication for testosterone in women is hypoactive sexual desire disorder in postmenopausal women. Evidence does not support using it for fatigue, mood, cognition, or bone health. There is no female-specific approved formulation in the United States, and the consensus advises that if it is used at all, blood levels should stay within the premenopausal physiological range rather than being pushed above it.

Primary sources

1. Executive summary of the Stages of Reproductive Aging Workshop +10. J Clin Endocrinol Metab, 2012. PMID 22344196.
2. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med, 2015. PMID 25686030.
3. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481.
4. The 2020 genitourinary syndrome of menopause position statement of NAMS. Menopause, 2020. PMID 32852449.
5. ACOG: Perimenopausal Bleeding and Bleeding After Menopause (patient FAQ).
6. ACOG: Heavy Menstrual Bleeding (patient FAQ).
7. ACOG Committee Opinion: Role of Transvaginal Ultrasonography in Evaluating the Endometrium With Postmenopausal Bleeding.
8. MedlinePlus: Primary ovarian insufficiency.
9. Office on Women's Health: Menopause basics.
10. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus. Obstet Gynecol, 2023. PMID 37856860.
11. National Academies: The Clinical Utility of Compounded Bioidentical Hormone Therapy.
12. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab, 2019. PMID 31498871.
13. Safety and efficacy of testosterone for women: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 2019. PMID 31353194.
14. International Society for the Study of Women's Sexual Health Clinical Practice Guideline. J Sex Med, 2021. PMID 33814355.
15. FDA prescribing information (estradiol vaginal ring), 2019.